接受同步化疗的头颈部鳞状细胞癌患者外周血淋巴细胞亚群变化

Although medical technology has improved the quality of life of HNSCC patients, their survival rate has not increased significantly, and their life and health continue to be threatened. With the help of modern medical technology, medical institutions can confirm the diagnosis of HNSCC patients in a timely manner, so as to take appropriate surgical treatment plans.

However, surgery is difficult for patients with recurrent or metastatic HNSCC, and concurrent chemotherapy alone is not effective for HNSCC patients.

Therefore, in this paper, the chemotherapy and immunotherapy of HNSCC patients were studied, and the following conclusions were drawn by detecting the peripheral blood lymphocytes of HNSCC patients. The NK cell (natural killer cell) index of healthy people was 6. 64% higher than that of HNSCC patients.

The CD4+/CD8+ ratio (CD4+ is inductive T cells and helper T cells, CD8+ is suppressor T cells and cytotoxic T cells) in HNSCC patients is in a downward trend during concurrent chemotherapy. Concurrent chemotherapy not only kills HNSCC cells, but also inhibits normal immune cells. The detection of peripheral blood lymphocytes of HNSCC patients has reference value for judging the immune function and curative effect of patients.